Type 1 Diabetes study: Dexcom G7 rtCGM
Official title A Study Comparing Dexcom Continuous Glucose Monitoring to Point of Care Glucose Testing for the Management of Hospital and Post-Discharge Subjects With Type 1 Diabetes
ClinicalTrials.gov ID: NCT06752928
What this study is testing
- What it's testing
- The study will see if using Dexcom CGM changes how well blood sugar stays in the target range and how often low blood sugar happens compared to usual point‑of‑care testing.
- Who it's for
- Adults with type 1 diabetes who have poor blood sugar control while in the hospital.
- What's involved
- Participants will wear a Dexcom G7 CGM device and also have regular blood glucose checks. They will be monitored during their hospital stay and after discharge.
- Time commitment
- The study lasts for the duration of the hospital stay and continues for a short period after discharge, with regular visits for device checks and blood tests.
Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Known history of T1D treated with insulin therapy (human regular or rapid-acting analogs or ultra-rapid analogs [lispro, aspart, glulisine...
- Admission diagnosis of T1D with poorly controlled diabetes (blood glucose \> 180 mg/dl, HbA1c \> 7%), including diabetic ketoacidosis (DKA) and...
- Expected length of hospital stay \> three days at the time of randomization
You likely can't join if
- Patients admitted to the ICU
- people using CGM technology before admission
- people with type 2 diabetes
- Treatment with systemic immunosuppressive agents
- Cystic fibrosis
- Prisoners
See the full eligibility criteria
- Known history of T1D treated with insulin therapy (human regular or rapid-acting analogs or ultra-rapid analogs [lispro, aspart, glulisine, fast-acting insulin aspart, insulin lispro]), intermediate-acting (NPH and...
- Admission diagnosis of T1D with poorly controlled diabetes (blood glucose \> 180 mg/dl, HbA1c \> 7%), including diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar state (HHS).
- Expected length of hospital stay \> three days at the time of randomization
- Patients admitted to the ICU
- people using CGM technology before admission
- people with type 2 diabetes
- Treatment with systemic immunosuppressive agents
- Cystic fibrosis
- Prisoners
- Patients expected to require MRI procedures during hospitalization.
- Female people who are pregnant or breastfeeding at enrollment into the study.
- people not willing to wear a CGM device
- people with clinically relevant hepatic disease (diagnosed liver cirrhosis and portal hypertension) and end-stage kidney disease (eGFR\< 30 ml/min), or terminal illness.
- people with a history of cognitive impairment, dementia, or mental condition rendering the subject unable to understand the nature and consequences of the study
The study team makes the final eligibility decision.
Where it is enrolling
- Atlanta, Georgia, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Atlanta, Georgia, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.